PRAX logo

PRAX Praxis Precision Medicines, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$300.43
-10.47 (-3.37%)

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABA…

Market Cap: $8.40Bwww.praxismedicines.com

Price

No data yet.

Social Signal Score

57
5d
60
2 mentions
—
30d
56
9 mentions
—
60d
56
9 mentions
—
90d
59
12 mentions
—
marketaux: 1 · news: 4 · rss: 7

Analyst Ratings

18 analysts
Buyconsensus
Strong Buy 0Buy 14Hold 3Sell 1Strong Sell 0
Avg price target$656.6+118.6%
Low $162Median $616High $1,201
Current Consensus

Revenue

$0.00
$0.00$2.49M$4.98M$7.46M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-13.11
$-13.58–$-12.07
11 analysts
FY2026
$-13.45
$-15.78–$-12.43
15 analysts
FY2027
$-10.91
$-18.13–$-3.67
15 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Marcio Silva De'Souza
Sector
Healthcare
Industry
Biotechnology
Employees
168
Beta
2.84
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
94.22
www.praxismedicines.com